Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of February 2026, specifically dated February 4, 2026. The report details a strategic partnership involving Evogene's subsidiary, Biomica Ltd., and Shanghai Lishan Biopharmaceuticals Co., Ltd. (Lishan Biotech).
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the announcement of a licensing agreement.
Material Changes
The primary material event is the execution of an exclusive worldwide licensing agreement between Biomica and Lishan Biotech for BMC128 (designated LS-LBP-002), a microbiome-based therapeutic intended to enhance anti-tumor immune activity. Under this agreement, Lishan Biotech receives exclusive rights to develop, manufacture, and commercialize the asset, subject to reaching certain commercial milestones.
Outlook and Management Commentary
Evogene expects to receive future payments contingent on the progress of Lishan Biotech's clinical trials and regulatory approvals. The payment structure includes:
- Development milestone payments.
- Sales milestone payments.
- Royalties on future product sales.
The filing incorporates a press release (Exhibit 99.1) containing statements from company leadership, though the text of those specific statements is excluded from the summary of this Form 6-K.
Investor Verification Checklist
- Verify the specific monetary values and timing of the development and sales milestones in the full agreement.
- Review the conditions attached to the royalty payments and commercial milestones.
- Examine the clinical trial status of BMC128 prior to this agreement.
- Assess the financial stability and development capabilities of Lishan Biotech as the new licensee.